BRAF | Department of Medicine Blog

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H,[...]

By afschroeder • May 28, 2026

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

By afschroeder • March 31, 2026

Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

By afschroeder • October 20, 2025

Pediatric low-grade glioma models: advances and ongoing challenges

Yvone GM, Breunig JJ. Pediatric low-grade glioma models: advances and ongoing challenges. Front Oncol. 2024 Jan 22;13:1346949. doi: 10.3389/fonc.2023.1346949. PMID: 38318325; PMCID: PMC10839015.

By sjmartinez • February 6, 2024